Multifactorial biological modulation of warm ischemia reperfusion injury in liver transplantation from non-heart-beating donors eliminates primary nonfunction and reduces bile salt toxicity

Annals of Surgery

Volumn 250, Issue 5, 2009, Pages 808-815

  Monbaliu, Diethard ^a   Vekemans, Katrien ^a   Hoekstra, Harm ^b   Vaahtera, Lauri ^c   Libbrecht, Louis ^d,e   Derveaux, Katelijne ^f   Parkkinen, Jaakko ^c   Liu, Qiang ^a   Heedfeld, Veerle ^a   Wylin, Tine ^a   Deckx, Hugo ^a   Zeegers, Marcel ^d   Balligand, Erika ^a   Buurman, Wim ^g   Van Pelt, Jos ^d   Porte, Robert J ^b   Pirenne, Jacques ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d UNIVERSITY OF LEUVEN   (Belgium)

^e GHENT UNIVERSITY HOSPITAL   (Belgium)

^f Stichting Jan Palfyn   (Belgium)

^g MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; AMINOTRANSFERASE; APOTRANSFERRIN; ASPARTATE AMINOTRANSFERASE; BILE SALT; GLUTATHIONE; GLYCINE; IRON; LACTIC ACID; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; OROSOMUCOID; PHOSPHOLIPID; PROSTACYCLIN; RINGER SOLUTION; STREPTOKINASE; TUMOR NECROSIS FACTOR ALPHA;

AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; CRYOPRESERVATION; FEMALE; GILT (SWINE); GRAFT SURVIVAL; KUPFFER CELL; LACTATE BLOOD LEVEL; LIVER FUNCTION; LIVER TRANSPLANTATION; NONHUMAN; ORGAN DONOR; PRIORITY JOURNAL; REPERFUSION INJURY; VASOCONSTRICTION;

ALPHA-TOCOPHEROL; ANIMALS; BILE ACIDS AND SALTS; FEMALE; FIBRINOLYTIC AGENTS; GLUTATHIONE; GLYCINE; GRAFT SURVIVAL; LIVER TRANSPLANTATION; OROSOMUCOID; PRIMARY GRAFT DYSFUNCTION; PYRAZOLES; PYRIDINES; REPERFUSION INJURY; STREPTOKINASE; SWINE; WARM ISCHEMIA;

EID: 70449440722     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e3181bdd787     Document Type: Article

References (63)

1. Durand F, Renz JF, Alkofer B, et al. Report of the Paris consensus meeting on expanded criteria donors in liver transplantation. Liver Transpl. 2008;14: 1694-1707.
2. Briceno J, Marchal T, Padillo J, et al. Influence of marginal donors on liver preservation injury. Transplantation. 2002;74:522-526.
3. Monbaliu D, Crabbe T, Roskams T, et al. Livers from non-heart-beating donors tolerate short periods of warm ischemia. Transplantation. 2005;79: 1226-1230.
4. Abt PL, Desai NM, Crawford MD, et al. Survival following liver transplantation from non-heart-beating donors. Ann Surg. 2004;239:87-92.
5. Moers C, Leuvenink HG, Ploeg RJ. Non-heart-beating organ donation: overview and future perspectives. Transpl Int. 2007;20:567-575.
6. Yska MJ, Buis CI, Monbaliu D, et al. The role of bile salt toxicity in the pathogenesis of bile duct injury after non-heart-beating porcine liver transplantation. Transplantation. 2008;85:1625-1631.
7. Monbaliu D, van Pelt J, De Vos R, et al. Primary graft nonfunction and Kupffer cell activation after liver transplantation from non-heart-beating donors in pigs. Liver Transpl. 2007;13:239-247.
8. Monbaliu DR, Dubuisson CN, Zeegers MM, et al. Increased serum phospholipase A2 activity after non-heart-beating donor liver transplantation and association with ischemia-reperfusion injury. J Surg Res. 2009;151:125-131.
9. Principles of Laboratory animal care. NIH publication 25 [No 28 revised] 1996.
10. Oike F, Uryuhara K, Otsuka M, et al. Simplified technique of orthotopic liver transplantation in pigs. Transplantation. 2001;71:328-331.
11. Yamauchi JI, Richter S, Vollmar B, et al. Warm preflush with streptokinase improves microvascular procurement and tissue integrity in liver graft retrieval from non-heart-beating donors. Transplantation. 2000;69: 1780-1784.
12. Yamauchi J, Schramm R, Richter S, et al. Improvement of microvascular graft equilibration and preservation in non-heart-beating donors by warm preflush with streptokinase. Transplantation. 2003;75:449-453.
13. Minor T, Hachenberg A, Tolba R, et al. Fibrinolytic preflush upon liver retrieval from non-heart beating donors to enhance postpreservation viability and energetic recovery upon reperfusion. Transplantation. 2001;71:1792-1796.
14. Gok MA, Shenton BK, Buckley PE, et al. How to improve the quality of kidneys from non-heart-beating donors: a randomised controlled trial of thrombolysis in non-heart-beating donors. Transplantation. 2003;76:1714-1719.
15. Klein M, Geoghegan J, Wangemann R, et al. Preconditioning of donor livers with prostaglandin I2 before retrieval decreases hepatocellular ischemia-reperfusion injury. Transplantation. 1999;67:1128-1132.
16. Schemmer P, Bradford BU, Rose ML, et al. Intravenous glycine improves survival in rat liver transplantation. Am J Physiol. 1999;276:G924-G932.
17. Schemmer P, Golling M, Kraus T, et al. Extended experience with glycine for prevention of reperfusion injury after human liver transplantation. Transplant Proc. 2002;34:2307-2309.
18. Schauer RJ, Gerbes AL, Vonier D, et al. Glutathione protects the rat liver against reperfusion injury after prolonged warm ischemia. Ann Surg. 2004; 239:220-231.
19. Schauer RJ, Kalmuk S, Gerbes AL, et al. Intravenous administration of glutathione protects parenchymal and non-parenchymal liver cells against reperfusion injury following rat liver transplantation. World J Gastroenterol. 2004;10:864-870.
20. de Vries B, Walter SJ, von Bonsdorff L, et al. Reduction of circulating redox-active iron by apotransferrin protects against renal ischemia-reperfu-sion injury. Transplantation. 2004;77:669-675.
21. Lemasters JJ. Rusty notions of cell injury. J Hepatol. 2004;40:696-698.
22. Eum HA, Lee SH, Lee SM, et al. Trolox C ameliorates hepatic drug metabolizing dysfunction after ischemia/reperfusion. Arch Pharm Res. 2002;25[6]:940-945.
23. Giakoustidis D, Papageorgiou G, Iliadis S, et al. Intramuscular administration of very high dose of alpha-tocopherol protects liver from severe ischemia/ reperfusion injury. World J Surg. 2002;26:872-877.
24. Ono H, Totsuka E, Hakamada K, et al. Attenuation of graft injury in porcine liver transplantation from non-heart beating donor by FR167653. Hepatogas-troenterology. 2005;52:885-892.
25. Esposito BP, Breuer W, Sirankapracha P, et al. Labile plasma iron in iron overload: redox activity and susceptibility to chelation. Blood. 2003;102: 2670-2677.
26. Turley SD, Dietschy JM. Re-evaluation of the 3 alpha-hydroxysteroid dehy-drogenase assay for total bile acids in bile. J Lipid Res. 1978;19:924-928.
27. Imber CJ, St Peter SD, Lopez de Cenarruzabeitia I, et al. Advantages of normothermic perfusion over cold storage in liver preservation. Transplantation. 2002;73:701-709.
28. Monbaliu D, Libbrecht L, De Vos R, et al. The extent of vacuolation in non-heart-beating porcine donor liver grafts prior to transplantation predicts their viability. Liver Transpl. 2008;14:1256-1265
29. Graft failure: etiology, recognition and treatment. In: Busuttil RW, Klintmalm G, eds. Transplantation of the Liver. 2nd ed. Philadelphia, PA: Elsevier Saunders; 2005:915-928.
30. Pirenne J, Gunson B, Khaleef H, et al. Influence of ischemia-reperfusion injury on rejection after liver transplantation. Transplant Proc. 1997;29:366-367. (Pubitemid 27123446)
31. Kim IK, Bedi DS, Denecke C, et al. Impact of innate and adaptive immunity on rejection and tolerance. Transplantation. 2008;86:889-894.
32. Selzner N, Rudiger H, Graf R, et al. Protective strategies against ischemic injury of the liver. Gastroenterology. 2003;125:917-936.
33. Casillas-Ramirez A, Mosbah IB, Ramalho F, et al. Past and future approaches to ischemia-reperfusion lesion associated with liver transplantation. Life Sci. 2006;79:1881-1894. (Pubitemid 44488610)
34. Karam G, Compagnon P, Hourmant M, et al. A single solution for multiple organ procurement and preservation. Transpl Int. 2005;18:657-663.
35. Bachmann S, Bechstein WO, Keck H, et al. Pilot study: Carolina Rinse Solution improves graft function after orthotopic liver transplantation in humans. Transplant Proc. 1997;29:390-392.
36. Kotsch K, Ulrich F, Reutzel-Selke A, et al. Methylprednisolone therapy in deceased donors reduces inflammation in the donor liver and improves outcome after liver transplantation: a prospective randomized controlled trial. Ann Surg. 2008;248:1042-1050.
37. Gu M, Takada Y, Fukunaga K, et al. Pharmacologic graft protection without donor pretreatment in liver transplantation from non-heart-beating donors. Transplantation. 2000;70:1021-1025.
38. Sato M, Ohkohchi N, Tsukamoto S, et al. Successful liver transplantation from agonal non-heart-beating donors in pigs. Transpl Int. 2003;16:100-107. (Pubitemid 36682205)
39. Baskin-Bey ES, Washburn K, Feng S, et al. Clinical Trial of the Pan-Caspase Inhibitor, IDN-6556, in Human Liver Preservation Injury. Am J Transplant. 2007;7:218-225.
40. Mehrabi A, Mood Z, Sadeghi M, et al. Thymoglobulin and ischemia reper-fusion injury in kidney and liver transplantation. Nephrol Dial Transplant. 2007;22 (suppl 8):viii54-viii60.
41. Gurusamy KS, Kumar Y, Sharma D, et al. Ischaemic preconditioning for liver transplantation. Cochrane Database Syst Rev. 2008:CD006315.
42. Akalin E, Bromberg JS. Gene therapy and solid-organ transplantation. Kidney Int. 2002;61:S56-S60.
43. Dutkowski P, de Rougemont O, Clavien PA. Machine perfusion for 'marginal' liver grafts. Am J Transplant. 2008;8:917-924.
44. Menger MD, Vollmar B. Pathomechanisms of ischemia-reperfusion injury as the basis for novel preventive strategies: is it time for the introduction of pleiotropic compounds? Transplant Proc. 2007;39:485-488.
45. Pirenne J, Van Gelder F, Coosemans W, et al. Type of donor aortic preservation solution and not cold ischemia time is a major determinant of biliary strictures after liver transplantation. Liver Transpl. 2001;7:540-545.
46. Tojimbara Wicomb WN, Garcia-Kennedy R, Burns W, et al. Liver transplantation from non-heart beating donors in rats: influence of viscosity and temperature of initial flushing solutions on graft function. Liver Transpl Surg. 1997;3:39-45.
47. Massip-Salcedo M, Rosello-Catafau J, Prieto J, et al. The response of the hepatocyte to ischemia. Liver Int. 2007;27:6-16.
48. Habib MM, Hodgson HJ, Davidson BR. The role of glycine in hepatic ischemia-reperfusion injury. Curr Pharm Des. 2006;12:2953-2967.
49. Currin RT, Caldwell-Kenkel JC, Lichtman SN, et al. Protection by Carolina rinse solution, acidotic pH, and glycine against lethal reperfusion injury to sinusoidal endothelial cells of rat livers stored for transplantation. Transplantation. 1996; 62:1549-1558.
50. Zhang Y, Ikejima K, Honda H, et al. Glycine prevents apoptosis of rat sinusoidal endothelial cells caused by deprivation of vascular endothelial growth factor. Hepatology. 2000;32:542-546.
51. Zhong Z, Wheeler MD, Li X, et al. L-Glycine: a novel antiinflammatory, immunomodulatory, and cytoprotective agent. Curr Opin Clin Nutr Metab Care. 2003;6:229-240.
52. Nishimura Y, Lemasters JJ. Glycine blocks opening of a death channel in cultured hepatic sinusoidal endothelial cells during chemical hypoxia. Cell Death Differ. 2001;8:850-858.
53. Schilling M. Glycine inhibits phospholipolysis of hypoxic membranes. Trans-plantationsmedizin. 1994;2:140.
54. Kobayashi M, Takeyoshi I, Yoshinari D, et al. P38 mitogen-activated protein kinase inhibition attenuates ischemia-reperfusion injury of the rat liver. Surgery. 2002;131:344-349.
55. Lai EW, Toledo-Pereyra LH, Walsh J, et al. The role of MAP kinases in trauma and ischemia-reperfusion. J Invest Surg. 2004;17:45-53.
56. Glantzounis GK, Salacinski HJ, Yang W, et al. The contemporary role of antioxidant therapy in attenuating liver ischemia-reperfusion injury: a review. Liver Transpl. 2005;11:1031-1047.
57. Libert C, Hochepied T, Berger FG, et al. High-level constitutive expression of alpha 1-acid glycoprotein and lack of protection against tumor necrosis factor-induced lethal shock in transgenic mice. Transgenic Res. 1998;7:429-435.
58. de Vries B, Walter SJ, Wolfs TG, et al. Exogenous alpha-1-acid glycoprotein protects against renal ischemia-reperfusion injury by inhibition of inflammation and apoptosis. Transplantation. 2004;78:1116-1124.
59. Hochepied T, Berger FG, Baumann H, et al. Alpha(1)-acid glycoprotein: an acute phase protein with inflammatory and immunomodulating properties. Cytokine Growth Factor Rev. 2003;14:25-34.
60. Geuken E, Visser D, Kuipers F, et al. Rapid increase of bile salt secretion is associated with bile duct injury after human liver transplantation. J Hepatol. 2004;41:1017-1025.
61. Hertl M, Harvey PR, Swanson PE, et al. Evidence of preservation injury to bile ducts by bile salts in the pig and its prevention by infusions of hydrophilic bile salts. Hepatology. 1995;21:1130-1137.
62. Hoekstra H, Porte RJ, Tian Y, et al. Bile salt toxicity aggravates cold ischemic injury of bile ducts after liver transplantation in Mdr2 +/- mice. Hepatology. 2006;43:1022-1031.
63. Buis CI, van der SG, Visser DS, et al. Heme oxygenase-1 genotype of the donor is associated with graft survival after liver transplantation. Am J Transplant. 2008;8:377-385.